Loading…
ProMIS Neurosciences, Inc. is projected to rise to $15.28 by 2027, a +5% move from its current price of $14.50. PMN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $13.90 | $14.50 | $15.12 | 0.00% |
| Jul 14 | $13.66 | $14.50 | $15.39 | +0.01% |
| Jul 15 | $13.48 | $14.50 | $15.60 | +0.01% |
| Jul 16 | $13.33 | $14.50 | $15.77 | +0.02% |
| Jul 17 | $13.20 | $14.50 | $15.93 | +0.02% |
| Jul 18 | $13.09 | $14.50 | $16.08 | +0.03% |
| Jul 19 | $12.98 | $14.50 | $16.21 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.98 | $14.50 | $16.21 | +0.03% |
| Week 2 | $12.40 | $14.51 | $16.98 | +0.07% |
| Week 3 | $11.97 | $14.51 | $17.60 | +0.10% |
| Week 4 | $11.62 | $14.52 | $18.14 | +0.13% |
| Week 5 | $11.33 | $14.52 | $18.62 | +0.16% |
| Week 6 | $11.06 | $14.53 | $19.08 | +0.20% |
| Week 7 | $10.83 | $14.53 | $19.50 | +0.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ProMIS Neurosciences, Inc. is a healthcare company based in Canada that discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases. Its proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
Its lead product candidates include PMN310, a monoclonal antibody for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a monoclonal antibody targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer’s. It is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia.
Formerly Amorfix Life Sciences Ltd., the company changed its name to ProMIS Neurosciences, Inc. in July 2015, and is headquartered in Toronto, Canada.
PMN is the publicly traded ticker for ProMIS Neurosciences, Inc., a healthcare company focused on antibody therapies and vaccines for neurodegenerative and misfolded protein diseases. The current price is $14.50, the market cap is $130.03M, and the stock ranks 4056 by market capitalization.
The near-term price outlook is reflected in a mixed to neutral view with a neutral sentiment overall, while the longer-term path shows potential upside in select years. The stock’s current technical picture sits against defined support and resistance levels, with a 30-day trading range that informs near-term volatility. An explicit multi-year forecast window presents year-by-year expectations for price and ROI through 2050.
A major floor 48.9% below — a decisive break under it would weaken the trend.
The nearest floor, 37.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.6% away) — a breakout level to watch.
A major ceiling 71.0% above — clearing it would confirm fresh momentum.
Key PMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.91 | Buy | $13.85 | Buy |
| MA 10 | $13.08 | Buy | $13.17 | Buy |
| MA 20 | $11.74 | Buy | $12.26 | Buy |
| MA 50 | $10.97 | Buy | $11.75 | Buy |
| MA 100 | $13.54 | Buy | $12.05 | Buy |
| MA 200 | $11.83 | Buy | $12.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.00 | Sell |
| Stoch RSI (14) | 98.92 | Sell |
| CCI (20) | 107.29 | Buy |
| Williams %R (14) | -0.50 | Info |
| MACD (12,26,9) | 0.35 | Buy |
| ROC (12) | 33.30 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 99.50 | Sell |
| TRIX (15) | 0.80 | Buy |
| Awesome (5,34) | 2.80 | Buy |
| Ultimate (7,14,28) | 81.65 | Sell |
| Momentum (10) | 4.00 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 14.35 | Buy |
| ADX (14) | 28.26 | Buy |
| ATR (14) | 0.34 | Info |
30-day technical picture:
- Sentiment: NEUTRAL
- RSI(14): 80
- SMA50: $10.97
- SMA200: $11.83
- Support: $9.13
- Resistance: $14.27
- 30-day range: $10.99 to $19.13
The price is trading above the SMA50 and SMA200, with the current price near the intermediate resistance level. The RSI at 80 suggests overbought pressure could be present, while the neutral sentiment indicates no clear directional bias in the very near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.14 | $14.50 | $18.96 | 0% | Neutral | |
| $11.56 | $15.28 | $21.70 | +5% | Neutral | |
| $9.38 | $12.99 | $19.44 | -10% | Neutral | |
| $9.11 | $13.11 | $20.44 | -10% | Neutral | |
| $9.31 | $13.87 | $22.37 | -4% | Neutral | |
| $9.58 | $14.72 | $24.45 | +2% | Neutral | |
| $11.38 | $18.02 | $30.72 | +24% | Bullish | |
| $11.50 | $18.73 | $32.69 | +29% | Bullish | |
| $10.82 | $18.11 | $32.31 | +25% | Bullish | |
| $9.97 | $17.14 | $31.18 | +18% | Neutral | |
| $12.52 | $24.38 | $48.15 | +68% | Bullish | |
| $20.45 | $45.44 | $100.87 | +213% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.14 | $14.50 | $17.41 | +0.00% |
| August 2026 | $11.71 | $14.03 | $17.41 | -3.22% |
| September 2026 | $12.02 | $14.56 | $18.37 | +3.77% |
| October 2026 | $12.40 | $15.16 | $19.38 | +4.07% |
| November 2026 | $12.00 | $14.79 | $19.13 | -2.44% |
| December 2026 | $11.68 | $14.50 | $18.96 | -1.94% |
Click any year to see its month-by-month PMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ProMIS Neurosciences, Inc.'s 2026 outlook centres on $14.50, within a $7.14 to $18.96 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PMN could reach as high as $21.70, with a base case around $15.28 and support toward $11.56 — roughly +5% from $14.50. A consolidation phase looks the most probable path here.
Expect PMN to range from $9.38 to $19.44 through 2028. The $12.99 average target implies a -10% move from current prices. That is -15% versus the projected 2027 average. Price action looks broadly range-bound.
The PMN price prediction for 2029 points to an average of $13.11 (low $9.11, high $20.44) — a potential decline of -10% on today's $14.50. A consolidation phase looks the most probable path here.
In 2030, PMN is projected to trade between $9.31 and $22.37, averaging $13.87 — a potential decline of -4% from today's $14.50. That is up +6% on the projected 2029 average. Price action looks broadly range-bound.
ProMIS Neurosciences, Inc.'s 2031 outlook centres on $14.72, within a $9.58 to $24.45 range. That is up +6% on the projected 2030 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, PMN could reach as high as $30.72, with a base case around $18.02 and support toward $11.38 — roughly +24% from $14.50. Momentum favours further upside here.
Expect PMN to range from $11.50 to $32.69 through 2033. The $18.73 average target implies a +29% move from current prices. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PMN price prediction for 2034 points to an average of $18.11 (low $10.82, high $32.31) — a potential gain of +25% on today's $14.50. Momentum favours further upside here.
In 2035, PMN is projected to trade between $9.97 and $31.18, averaging $17.14 — a potential gain of +18% from today's $14.50. That is -5% versus the projected 2034 average. A consolidation phase looks the most probable path here.
ProMIS Neurosciences, Inc.'s 2040 outlook centres on $24.38, within a $12.52 to $48.15 range. That is up +42% on the projected 2035 average. That marks a +68% change versus current levels. Momentum favours further upside here.
By 2050, PMN could reach as high as $100.87, with a base case around $45.44 and support toward $20.45 — roughly +213% from $14.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in PMN today (≈ 68.965517 PMN) could be worth
$3,133.99
+$2,133.99 (+213%) by 2050 · US Dollar
Based on the average projected PMN price of $45.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMNwould be worth at today's price.
$1,000 invested in PMN on Jul 10, 2025 (≈ 100 PMN) would be worth
$1,450
+$450 (+45.0%) today · 1.45× · US Dollar
Based on a PMN entry price of $10 vs. today's $14.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.35 | $1,086.14 | +8.6% |
| 1 month ago | $10.2 | $1,421.57 | +42.2% |
| 3 months ago | $12.6 | $1,150.79 | +15.1% |
| 6 months ago | $8.21 | $1,766.14 | +76.6% |
| 1 year ago | $10 | $1,450 | +45.0% |
| All time (5.0y) ago | $240 | $60.42 | -94.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMN forecast.
Our base-case forecast reaches $29.00 around 2050.
Implied market cap at $29.00: $260.06M
Multi-year forecast highlights the following perspectives:
- 2026: avg $14.50, min $7.14, max $18.96, ROI 0%, sentiment NEUTRAL
- 2027: avg $15.28, min $11.56, max $21.70, ROI 5.4%, sentiment NEUTRAL
- 2028: avg $12.99, min $9.38, max $19.44, ROI -10.4%, sentiment NEUTRAL
- 2029: avg $13.11, min $9.11, max $20.44, ROI -9.6%, sentiment NEUTRAL
- 2030: avg $13.87, min $9.31, max $22.37, ROI -4.4%, sentiment NEUTRAL
- 2031: avg $14.72, min $9.58, max $24.45, ROI 1.5%, sentiment NEUTRAL
- 2032: avg $18.02, min $11.38, max $30.72, ROI 24.3%, sentiment BULLISH
- 2033: avg $18.73, min $11.50, max $32.69, ROI 29.2%, sentiment BULLISH
- 2034: avg $18.11, min $10.82, max $32.31, ROI 24.9%, sentiment BULLISH
- 2035: avg $17.14, min $9.97, max $31.18, ROI 18.2%, sentiment NEUTRAL
- 2040: avg $24.38, min $12.52, max $48.15, ROI 68.1%, sentiment BULLISH
- 2050: avg $45.44, min $20.45, max $100.87, ROI 213.4%, sentiment BULLISH
Overall, the forecast shows a path with neutral to bullish years beginning around 2032, escalating into stronger upside by 2040 and dramatically by 2050. The upside is tempered in the earlier years by mixed returns, with some negative ROI years, highlighting the inherent uncertainty in long-horizon equity-like forecasts.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $13.87 with a range from $9.31 to $22.37 and an estimated ROI of -4.4%. The sentiment is Neutral.
The forecast presents a mixed outlook: several years show neutral sentiment and modest or negative ROI (for example, 2028 ROI -10.4% and 2029 ROI -9.6%), while later years show stronger upside (2032 ROI 24.3%, 2040 ROI 68.1%, and 2050 ROI 213.4%). These are estimates, not guarantees, and should be weighed against risk tolerance.
Yes, the maximum forecast in 2050 is $100.87, indicating the possibility of reaching above $100 in the outlook. The 2050 avg is $45.44 with a high of $100.87.
PMN’s current price is $14.50 and its market cap is $130.03M.
The 30-day range is $10.99 to $19.13. RSI(14) is 80, SMA50 is $10.97, SMA200 is $11.83, with a support at $9.13 and resistance at $14.27. The sentiment is NEUTRAL.
ProMIS Neurosciences, Inc. Community Discussion
0Share your ProMIS Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.